-
[show abstract]
[hide abstract]
ABSTRACT: As a rare benign lung tumor, pulmonary sclerosing hemangioma (PSH) occurs predominantly in Asian women in their fifth and sixth decades of life. PSH is considered to be evolved from primitive undifferentiated respiratory epithelium. In this study, we summarized our experience in 89 cases of PSH.
There were a total of 89 patients who received surgical resection and were histopathologically diagnosed as PSH during the period January 2001 to December 2010 in department of thoracic surgery, Cancer Institute and Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences. The clinical data of these patients including symptoms, disease courses, image characteristics and surgical procedures were collected and reviewed retrospectively.
The PSHs were most frequently (50.6%) found in the patients aged 41 to 60 years with a median age of 51 years (range: 24 - 71), and the sex ratio (male/female) was approximately 1:7 in this series. In the 89 patients, 53 (59.6%) were asymptomatic while the other 36 (40.4%) had some non-special symptoms such as cough (30.3%), hemoptysis (24.7%). There were only 3 cases (3.4%) with multiple PSHs, 4 cases (4.5%) combined with synchronous primary lung cancer, and 13 cases (14.6%) with lesions located in the hilar region. The median diameter of the 92 lesions was 2.3 cm (range: 0.3 - 6.0 cm), of which 38% located in the right lower lobe and 26.1% in the right middle lobe, and only about 1/3 were assumed as PSHs preoperatively based on CT imaging. One of the five patients who underwent PET-CT scan had been misdiagnosed as malignant. Of the 92 lesions, 47 were resected by enucleation, 29 by wedge resection, 14 by lobectomy, and 2 by pneumonectomy.
PSH frequently occurs in the middle-aged women. Most individuals with PSH are asymptomatic or have some non-specific symptoms. Their lesions are usually found accidentally by chest imaging. Although PSH often shows typical imaging characteristics of benign neoplasm of the lung, it is difficult to establish a defined pathological diagnosis preoperatively. The significant error or deferred rate of intraoperative frozen-section evaluation for PSH may result in some unnecessarily extensive surgical procedures. The complete surgical resection is considered the only effective treatment for PSH, and the normal pulmonary tissue should be reserved as possible.
Zhonghua yi xue za zhi 05/2012; 92(17):1190-3.
-
Ju-wei Mu, Ning Li,
Fang Lu,
You-sheng Mao,
Qi Xue,
Shu-geng Gao,
Jun Zhao,
Da-li Wang,
Zhi-shan Li,
Wen-dong Lei,
Yu-shu Gao,
Liang-ze Zhang,
Jin-feng Huang,
Kang Shao,
Kai Su,
Kun Yang,
Jian Li,
Gui-yu Cheng,
Ke-lin Sun,
Jie He
[show abstract]
[hide abstract]
ABSTRACT: ObjectiveTo evaluate the indication and short-term outcomes of video assisted thoracic surgery (VATS) for lung tumors.
MethodsData of 306 consecutive patients undergoing VATS pulmonary resection between January 2009 and August 2010 in Cancer Institute
& Hospital, Chinese Academy of Medical Sciences were retrospectively reviewed.
ResultsThere were 7 patients who underwent open thoracotomy, accounting for 2.29% (7/306). The overall morbidity rate of complications
and the mortality rate induced by VATS was 1.63% (5/306) and 0.33% (1/306), respectively. There were no significant differences
in morbidity and mortality rate between the patients receiving the VATS and the patients receiving the OT. The overall hospitalization,
postoperative length of stay (LOS) and chest tube duration in the VATS lobectomy group (n = 167) were shorter than those in the open thoracotomy (OT), but the operative time in the VATS group was longer than that
in the OT group (n = 124). There were no significant differences in the number of station of lymph nodal dissection (LND) and number of LND
in pathological stage I between VATS group and OT group, but significant differences were found in the number of station of
LND and the number of LND in pathological stage II and stage IIIA between the 2 groups. Compared with those who underwent
OT wedge resection (n = 72), the patients who underwent VATS wedge resection (n = 108) had shorter operative time, chest tube duration and hospital LOS, and there were no significant differences in morbidity
of the complications and mortality between the 2 groups.
ConclusionVATS lobectomy can be performed for patients with clinical stage I lung cancer (with tumor diameter smaller than 5 cm, without
hilar and mediastinal lymph node enlargement). VATS lobectomy is superior to OT lobectomy in short-term outcomes, although
further studies exploring long-term outcomes through longer follow-up is needed to determine the oncologic equivalency between
the VATS and the open lobectomy. VATS is also superior to OT in pulmonary wedge resection.
Key Wordsthoracic surgery-video-assisted-lung neoplasms-thoracotomy
Clinical Oncology and Cancer Research 04/2012; 7(5):310-316.
-
Ju-wei Mu,
Bai-hua Zhang, Ning Li,
Fang Lü,
You-sheng Mao,
Qi Xue,
Shu-geng Gao,
Jun Zhao,
Da-li Wang,
Zhi-shan Li,
Yu-shun Gao,
Liang-ze Zhang,
Jin-feng Huang,
Kang Shao,
Fei-yue Feng,
Liang Zhao,
Jian Li,
Gui-yu Cheng,
Ke-lin Sun,
Jie He
[show abstract]
[hide abstract]
ABSTRACT: To compare the short-term outcomes of surgical treatment for non-small cell lung cancer (NSCLC) by video-assisted thoracoscopic surgery (VATS) and open thoracotomy (OT).
Data of 737 consecutive NSCLC patients who underwent surgical treatment for non-small cell lung cancer by video-assisted thoracoscopic surgery and 630 patients who underwent pulmonary resection via open thoracotomy (as controls) in Cancer Institute & Hospital, Chinese Academy of Medical Sciences between January 2009 and August 2011 were retrospectively reviewed. The risk factors after lobectomy were also analyzed.
In the 506 NSCLC patients who received VATS lobectomy, postoperative complications occurred in 13 patients (2.6%) and one patient died of acute respiratory distress syndrome (0.2%). In the 521 patients who received open thoracotomy (OT) lobectomy, postoperative complications occurred in 21 patients (4.0%) and one patient died of pulmonary infection (0.2%). There was no significant difference in the morbidity rate (P > 0.05) and mortality rate (P > 0.05) between the VATS group and OT group. In the 190 patients who received VATS wedge resections, postoperative complications occurred in 3 patients (1.6%). One hundred and nine patients received OT wedge resections. Postoperative complications occurred in 4 patients (3.7%). There were no significant differences for morbidity rate (P = 0.262) between these two groups, and there was no perioperative death in these two groups. Univariate and multivariate analyses demonstrated that age (OR = 1.047, 95%CI: 1.004 - 1.091), history of smoking (OR = 6.374, 95%CI: 2.588 - 15.695) and operation time (OR = 1.418, 95%CI: 1.075 - 1.871) were independent risk factors of postoperative complications.
To compare with the NSCLC patients who should undergo lobectomy or wedge resection via open thoracotomy, a similar short-term outcome can be achieved via VATS approach.
Zhonghua zhong liu za zhi [Chinese journal of oncology] 04/2012; 34(4):301-5.
-
Fengwei Tan,
Ying Jiang,
Nan Sun,
Zhaoli Chen,
Yongzhuang Lv,
Kang Shao, Ning Li,
Bin Qiu,
Yibo Gao,
Baozhong Li, [......],
Fang Zhou,
Zhen Wang,
Dapeng Ding,
Jiwen Wang,
Jian Sun,
Jie Hang,
Susheng Shi,
Xiaoli Feng,
Fuchu He,
Jie He
[show abstract]
[hide abstract]
ABSTRACT: Lung cancer is the leading cause of cancer-related death in the world. To explore tumor biomarkers for clinical application, two-dimensional fluorescence difference gel electrophoresis and subsequent MALDI-TOF/TOF mass spectrometry were performed to identify proteins differentially expressed in 12 pairs of lung squamous cell tumors and their corresponding normal tissues. A total of 28 nonredundant proteins were identified with significant alteration in lung tumors. The up-regulation of isocitrate dehydrogenase 1 (IDH1), superoxide dismutase 2, 14-3-3ε, and receptor of activated protein kinase C1 and the down-regulation of peroxiredoxin 2 in tumors were validated by RT-PCR and Western blot analysis in independent 15 pairs of samples. Increased IDH1 expression was further verified by the immunohistochemical study in extended 73 squamous cell carcinoma and 64 adenocarcinoma clinical samples. A correlation between IDH1 expression and poor overall survival of non-small cell lung cancer (NSCLC) patients was observed. Furthermore, ELISA analysis showed that the plasma level of IDH1 was significantly elevated in NSCLC patients compared with benign lung disease patients and healthy individuals. In addition, knockdown of IDH1 by RNA interference suppressed the proliferation of NSCLC cell line and decreased the growth of xenograft tumors in vivo. These observations suggested that IDH1, as a protein promoting tumor growth, could be used as a plasma biomarker for diagnosis and a histochemical biomarker for prognosis prediction of NSCLC.
Molecular & Cellular Proteomics 11/2011; 11(2):M111.008821. · 7.40 Impact Factor
-
Xiaogang Tan,
Wenyan Qin,
Liang Zhang,
Jie Hang,
Baozhong Li,
Cuiyan Zhang,
Junting Wan,
Fang Zhou,
Kang Shao,
Yimin Sun, [......],
Susheng Shi,
Xiaoli Feng,
Shouhua Zhao,
Zhen Wang,
Xiaohong Zhao,
Zhaoli Chen,
Keith Mitchelson,
Jing Cheng,
Yong Guo,
Jie He
[show abstract]
[hide abstract]
ABSTRACT: Recent studies have suggested that microRNA biomarkers could be useful for stratifying lung cancer subtypes, but microRNA signatures varied between different populations. Squamous cell carcinoma (SCC) is one major subtype of lung cancer that urgently needs biomarkers to aid patient management. Here, we undertook the first comprehensive investigation on microRNA in Chinese SCC patients.
MicroRNA expression was measured in cancerous and noncancerous tissue pairs strictly collected from Chinese SCC patients (stages I-III), who had not been treated with chemotherapy or radiotherapy prior to surgery. The molecular targets of proposed microRNA were further examined.
We identified a 5-microRNA classifier (hsa-miR-210, hsa-miR-182, hsa-miR-486-5p, hsa-miR-30a, and hsa-miR-140-3p) that could distinguish SCC from normal lung tissues. The classifier had an accuracy of 94.1% in a training cohort (34 patients) and 96.2% in a test cohort (26 patients). We also showed that high expression of hsa-miR-31 was associated with poor survival in these 60 SCC patients by Kaplan-Meier analysis (P = 0.007), by univariate Cox analysis (P = 0.011), and by multivariate Cox analysis (P = 0.011). This association was independently validated in a separate cohort of 88 SCC patients (P = 0.008, 0.011, and 0.003 in Kaplan-Meier analysis, univariate Cox analysis, and multivariate Cox analysis, respectively). We then determined that the tumor suppressor DICER1 is a target of hsa-miR-31. Expression of hsa-miR-31 in a human lung cancer cell line repressed DICER1 activity but not PPP2R2A or LATS2.
Our results identified a new diagnostic microRNA classifier for SCC among Chinese patients and a new prognostic biomarker, hsa-miR-31.
Clinical Cancer Research 09/2011; 17(21):6802-11. · 7.74 Impact Factor
-
Da-Peng Ding,
Zhao-Li Chen,
Xiao-Hong Zhao,
Ji-Wen Wang,
Jian Sun,
Zhen Wang,
Feng-Wei Tan,
Xiao-Gang Tan,
Bao-Zhong Li,
Fang Zhou,
Kang Shao, Ning Li,
Bin Qiu,
Jie He
[show abstract]
[hide abstract]
ABSTRACT: Cyclin E is reported to be an important cell cycle regulator, and its dysregulation is implicated in tumorigenesis including esophageal squamous cell carcinoma (ESCC). MicroRNAs (miRNAs) regulate gene expression at the posttranscriptional level and play important roles in tumor initiation and progression. However, the regulation of cyclin E by miRNAs is still unclear in ESCC. In the present study, we found that overexpression of miR-29c inhibited cyclin E expression by targeting 3' untranslated region of cyclin E messenger RNA in ESCC cells. Moreover, overexpression of miR-29c induced cell cycle G(1)/G(0) arrest through suppression of cyclin E expression, without affecting other G(1) phase-related proteins level, such as cyclin D1, cyclin D2, cyclin dependent kinase (CDK) 2 and CDK6. Furthermore, we demonstrated that overexpression of miR-29c inhibited proliferation of ESCC cells in vitro and in vivo. In addition, we detected miR-29c expression in 26 pairs of esophageal tumor-in-site-tissues and 60 pairs of ESCC tissues. The result showed that miR-29c level significantly decreased in ESCC tumor tissues and cell lines compared with normal esophageal epithelia. Taken together, our findings indicated that miR-29c was frequently downregulated in ESCC tissues and cells and suppressed tumor growth by inducing cell cycle G(1)/G(0) arrest mainly through modulating cyclin E expression.
Carcinogenesis 05/2011; 32(7):1025-32. · 5.70 Impact Factor
-
Zhen Wang,
Zhaoli Chen,
Yushun Gao, Ning Li,
Baozhong Li,
Fengwei Tan,
Xiaogang Tan,
Ning Lu,
Yuntian Sun,
Jian Sun,
Nan Sun,
Jie He
[show abstract]
[hide abstract]
ABSTRACT: Lung cancer is the leading cause of cancer-related death in the world and approximately 30-40% of patients with stage Ⅰ non-small cell lung cancer (NSCLC) die of recurrent disease. miRNA expression profiles can be diagnostic and prognostic markers of lung cancer. Recently, miR-34 family has been shown to be part of the p53 pathway which is frequently involved in lung cancer, and the expression of miR-34 has been reported to be regulated by DNA methylation. In present study, we investigated the correlation between DNA methylation status of miR-34 family and recurrence of stage Ⅰ NSCLC patients. miR-34a and miR-34b/c promoter methylation status were determined by nested methylation-specific PCR in FFPE tumor tissues from 161 patients of stage Ⅰ NSCLC. Furthermore, mature miR-34b and miR-34c expression were analyzed by qRT-PCR in the same panel tissues. Our results revealed that aberrant DNA methylation of miR-34b/c was correlated with a high probability of recurrence (p = 0.026) and associated with poor overall survival (p = 0.010) and disease-free survival (p = 0.017). No significant association was found for miR-34a methylation. Multivariate analysis showed that promoter hypermethylation of miR-34b/c was an independent prognostic factor of stage Ⅰ NSCLC. Moreover, no significant association between mature miR-34b and miR-34c expression and DNA methylation status was found. In conclusion, we have identified promoter hypermethylation of miR-34b/c as a relatively common event in NSCLC and might be a potential prognostic factor for stage Ⅰ NSCLC.
Cancer biology & therapy 03/2011; 11(5):490-6. · 2.64 Impact Factor
-
Ning Li,
Kang Shao,
Zhaoli Chen,
Bin Qiu,
Zhen Wang,
Fengwei Tan,
Jiwen Wang,
Xiaogang Tan,
Baozhong Li,
Meihua Xiong,
Fang Zhou,
Jie He
[show abstract]
[hide abstract]
ABSTRACT: The purpose of this study is to investigate the impact of positive cancer/lung cancer family history (FH) on clinical features and outcome in non-small cell lung cancer (NSCLC) patients. We analyzed 4,491 NSCLC patients with NSCLC who presented from January 1999-December 2005. Chi-square test and Wilcoxon test were used for univariate comparisons, while Cox Proportional Hazards regression analysis was performed to evaluate the adjusted risk of death. Univariate probability of survival was calculated using Kaplan-Meier estimate and compared using the log-rank test. Of 4,491 patients, 579 patients (12.89%) had positive FH, including 233 patients (5.19%) with FH of lung cancer. Patients with positive lung cancer FH, compared to those with negative FH, were diagnosed at earlier age (57 vs. 60; P < 0.001), presented more cases of adenocarcinoma (58.80 vs. 50.69%; P = 0.016), and at more advanced stage (Stage IIIB/IV 45.74 vs. 36.79%; P < 0.001). These differences were also detected in patients with positive cancer FH. In addition, more females and non-smokers were among patients with positive cancer FH (30.05 vs. 26.15%; P = 0.045 and 39.90 vs. 33.82%; P = 0.008, respectively). Furthermore, patients with advanced cancer (stage IIIB/IV) who had positive FH had lower response rate to chemotherapy (CR&PR 24.68 vs. 34.42%; P = 0.024). Nevertheless, patients with positive lung cancer FH had better prognosis (P = 0.015), especially if diagnosed at an early stage (P = 0.035), and their adjusted relative risk of death was lower (RR 0.69; 95% CI: 0.51-0.93; P = 0.015). Definite epidemiologic and survival differences exist between NSCLC patients with positive or negative FH of cancer. Our results suggest that cancer FH is an important factor of clinical features, and could serve as a prognostic indicator for NSCLC.
Familial Cancer 11/2010; 10(2):331-6. · 1.30 Impact Factor
-
Ju-wei Mu, Ning Li,
Kang Shao,
You-sheng Mao,
Shu-geng Gao,
Qi Xue,
Zhi-shan Li,
Jun Zhao,
Wen-dong Lei,
Yu-shun Gao,
Liang-ze Zhang,
Jin-feng Huang,
Kai Su,
Kun Yang,
Jian Li,
Gui-yu Cheng,
Ke-lin Sun,
Jie He
[show abstract]
[hide abstract]
ABSTRACT: To evaluate the indication and safety of video assisted thoracic surgery (VATS) for chest tumors.
Data of 144 consecutive patients receiving VATS between January and November 2009 in Cancer hospital Chinese Academy of Medical Sciences were retrospectively reviewed.
There was no conversion to open thoracotomy. Overall morbidity rate was 2.08% (3/144) and mortality rate was 0.69% (1/144). There were no significant differences for operative time, number of nodal dissection, morbidity rate, mortality rate, overall hospitalization and postoperative length of stay between VATS lobectomy group and open thoracotomy (OT) lobectomy group. Chest tube duration was shorter in the VATS lobectomy group than OT lobectomy group and more early-stage lung cancer patients were found in VATS group. There were no significant differences for number of nodal dissection, chest tube duration, morbidity rate, mortality rate, and postoperative length of stay between VATS lung wedge resection group and OT lung wedge resection group. Operative time and overall hospitalization were shorter in the VATS wedge resection group than OT wedge resection group.
Morbidity and mortality rate of VATS were acceptable. VATS lobectomy can be used as an alternative surgical technique for early-stage lung cancer. For lung wedge resection, VATS was superior than OT.
Zhonghua yi xue za zhi 03/2010; 90(9):621-3.
-
[show abstract]
[hide abstract]
ABSTRACT: ObjectiveA retrospective study was performed to analyze the impact of vascular invasion on prognosis in a series of radically resected
non-small cell lung cancer (NSCLC) and the subgroup of T1-4 nodal negative NSCLC patients.
MethodsA total of 259 NSCLC patients who had undergone radical resection were entered into this study. Detailed clinical data including
five-year survival were obtained for all the patients. The tumors were reviewed for the presence or absence of vascular invasion.
Fisher’s exact tests were used to assess the relationship between vascular invasion and other clinicopathological variables.
Survival time was defined as the interval from the date of operation to either death from lung cancer or the last follow-up.
Univariate analysis of survival curve was performed by the Kaplan-Meier method using the Log rank test. Multivariate survival
analysis was carried out by Cox regression. P<0.05 was considered statistically significant.
ResultsIn 259 patients, 33 cases were diagnosed as having vascular invasion. The overall 5-year survival was 37.5%. Patients with
vascular invasion had a median survival of 20 months compared with 43 months for those without vascular invasion (P<0.01). Multivariate analysis indicated that vascular invasion was a significant independent prognostic predictor for shortened
cancer-related survival in the patients. The relative risk for cancer-related survival was 2.2-fold greater in patients with
vascular invasion (95% CI: 1.45-3.32). Subgroup analysis revealed that patients with vascular invasion had a 5-year survival
of 11.1% compared with 57.1% for those without vascular invasion in the resected lung cancer patients at T1-4N0M0 (P=0.002).
ConclusionVascular invasion can serve as an independent prognostic factor in radically resected NSCLC.
Chinese Journal of Cancer Research 02/2008; 20(1):33-38. · 0.18 Impact Factor
-
Yong Guo,
Zhaoli Chen,
Liang Zhang,
Fang Zhou,
Susheng Shi,
Xiaoli Feng,
Baozhong Li,
Xin Meng,
Xi Ma,
Mingyong Luo,
Kang Shao, Ning Li,
Bin Qiu,
Keith Mitchelson,
Jing Cheng,
Jie He
[show abstract]
[hide abstract]
ABSTRACT: Esophageal cancer is the sixth leading cause of death from cancer and one of the least studied cancers worldwide. The global microRNA expression profile of esophageal cancer has not been reported previously. Here, for the first time, we have investigated expressed microRNAs in cryopreserved esophageal cancer tissues using advanced microRNA microarray techniques. Our microarray analyses identified seven microRNAs that could distinguish malignant esophageal cancer lesions from adjacent normal tissues. Some microRNAs could be correlated with the different clinicopathologic classifications. High expression of hsa-miR-103/107 correlated with poor survival by univariate analysis as well as by multivariate analysis. These results indicate that microRNA expression profiles are important diagnostic and prognostic markers of esophageal cancer, which might be analyzed simply using economical approaches such as reverse transcription-PCR.
Cancer Research 02/2008; 68(1):26-33. · 7.86 Impact Factor
-
Cuiyan Zhang,
Fang Zhou, Ning Li,
Susheng Shi,
Xiaoli Feng,
Zhaoli Chen,
Jie Hang,
Bin Qiu,
Baozhong Li,
Sheng Chang,
Junting Wan,
Kang Shao,
Xuezhong Xing,
Xiaogang Tan,
Zhen Wang,
Meihua Xiong,
Jie He
[show abstract]
[hide abstract]
ABSTRACT: Increasing evidence has suggested that RhoE plays an important role in carcinogenesis and progression. However, the correlation between RhoE expression and clinical outcome in lung cancer has not been investigated.
RhoE expression was detected by immunohistochemistry on tissue microarray containing samples from 115 patients with non-small cell lung cancer with a median follow-up of 54 months.
RhoE was overexpressed in the cytoplasm of lung cancer cells compared with undetectable expression of RhoE in the adjacent nontumoral cells. Patients with RhoE-negative tumors had substantially longer cancer-related survival than did patients with RhoE-positive tumors. Multivariate analysis showed that RhoE overexpression was an independent marker for cancer-related survival in the entire population after adjusting for other prognostic factors.
RhoE expression may serve as an unfavorable prognostic factor in patients with non-small cell lung cancer.
Annals of Surgical Oncology 10/2007; 14(9):2628-35. · 4.17 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: FUS2 gene locating at 3p21.3 is considered a promising candidate tumor suppressor gene. The aim of this study is to examine the difference in FUS2-767A/T polymorphism site between lung cancer patients and normal controls in Chinese population.
The genotype FUS2-767A/T was detected in 146 lung cancer patients and 113 normal controls by PCR-SSCP method. The relationship between lung cancer risk and difference in genotypes of FUS2 gene was analysed.
FUS2-767A/T was significantly related to histological type (P=0.044), age of the patients with lung cancer (P=0.011) and vessel cancer embolus (P=0.031) in lung cancer group. There was no significant difference in distribution of FUS2 genotypes between lung cancer patients and normal controls (P=0.945).
The results suggest that the FUS2-767A/T polymorphism may be a susceptibility factor for lung cancer among Chinese population.
Zhongguo fei ai za zhi = Chinese journal of lung cancer 10/2006; 9(5):409-12.
